Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders |
Jeong, Hui Su
(Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University)
Kim, Hye Jin (Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University) Kim, Deok-Ho (Department of Biomedical Engineering, Johns Hopkins University) Chung, Ki Wha (Department of Biological Sciences, Kongju National University) Choi, Byung-Ok (Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University) Lee, Ji Eun (Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University) |
1 | Cirrincione, A.M., Pellegrini, A.D., Dominy, J.R., Benjamin, M.E., Utkina-Sosunova, I., Lotti, F., Jergova, S., Sagen, J., and Rieger, S. (2020). Paclitaxel-induced peripheral neuropathy is caused by epidermal ROS and mitochondrial damage through conserved MMP-13 activation. Sci. Rep. 10, 3970. DOI |
2 | Grice, S.J., Sleigh, J.N., Motley, W.W., Liu, J.L., Burgess, R.W., Talbot, K., and Cader, M.Z. (2015). Dominant, toxic gain-of-function mutations in gars lead to non-cell autonomous neuropathology. Hum. Mol. Genet. 24, 4397-4406. DOI |
3 | Ha, N., Choi, Y.I., Jung, N., Song, J.Y., Bae, D.K., Kim, M.C., Lee, Y.J., Song, H., Kwak, G., Jeong, S., et al. (2020). A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A. Br. J. Pharmacol. 177, 5096-5113. DOI |
4 | He, W., Bai, G., Zhou, H., Wei, N., White, N.M., Lauer, J., Liu, H., Shi, Y., Dumitru, C.D., Lettieri, K., et al. (2015). CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. Nature 526, 710-714. DOI |
5 | Lee, H.J., Park, J., Nakhro, K., Park, J.M., Hur, Y.M., Choi, B.O., and Chung, K.W. (2012). Two novel mutations of GARS in Korean families with distal hereditary motor neuropathy type V. J. Peripher. Nerv. Syst. 17, 418-421. DOI |
6 | Janke, C. and Bulinski, J.C. (2011). Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat. Rev. Mol. Cell Biol. 12, 773-786. DOI |
7 | Antonellis, A., Lee-Lin, S.Q., Wasterlain, A., Leo, P., Quezado, M., Goldfarb, L.G., Myung, K., Burgess, S., Fischbeck, K.H., and Green, E.D. (2006). Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. J. Neurosci. 26, 10397-10406. DOI |
8 | Licciardi, P.V. and Karagiannis, T.C. (2012). Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol. 2012, 690901. DOI |
9 | Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., and Pazdur, R. (2007). FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247-1252. DOI |
10 | Niehues, S., Bussmann, J., Steffes, G., Erdmann, I., Kohrer, C., Sun, L., Wagner, M., Schafer, K., Wang, G., Koerdt, S.N., et al. (2015). Impaired protein translation in Drosophila models for Charcot-Marie-Tooth neuropathy caused by mutant tRNA synthetases. Nat. Commun. 6, 7520. DOI |
11 | Morena, J., Gupta, A., and Hoyle, J.C. (2019). Charcot-Marie-Tooth: from molecules to therapy. Int. J. Mol. Sci. 20, 3419. DOI |
12 | Vilmont, V., Cadot, B., Vezin, E., Le Grand, F., and Gomes, E.R. (2016). Dynein disruption perturbs post-synaptic components and contributes to impaired MuSK clustering at the NMJ: implication in ALS. Sci. Rep. 6, 27804. DOI |
13 | Bremer, J., Skinner, J., and Granato, M. (2017). A small molecule screen identifies in vivo modulators of peripheral nerve regeneration in zebrafish. PLoS One 12, e0178854. DOI |
14 | Mariadason, J.M. (2008). HDACs and HDAC inhibitors in colon cancer. Epigenetics 3, 28-37. DOI |
15 | Menelaou, E., Husbands, E.E., Pollet, R.G., Coutts, C.A., Ali, D.W., and Svoboda, K.R. (2008). Embryonic motor activity and implications for regulating motoneuron axonal pathfinding in zebrafish. Eur. J. Neurosci. 28, 1080-1096. DOI |
16 | Mo, Z., Zhao, X., Liu, H., Hu, Q., Chen, X.Q., Pham, J., Wei, N., Liu, Z., Zhou, J., Burgess, R.W., et al. (2018). Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy. Nat. Commun. 9, 1007. DOI |
17 | Namdar, M., Perez, G., Ngo, L., and Marks, P.A. (2010). Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc. Natl. Acad. Sci. U. S. A. 107, 20003-20008. DOI |
18 | Ponomareva, O.Y., Eliceiri, K.W., and Halloran, M.C. (2016). Charcot-Marie-Tooth 2b associated Rab7 mutations cause axon growth and guidance defects during vertebrate sensory neuron development. Neural Dev. 11, 2. DOI |
19 | Rodriguez Cruz, P.M., Cossins, J., Beeson, D., and Vincent, A. (2020). The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis. Front. Mol. Neurosci. 13, 610964. DOI |
20 | Simoes-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.A., and Cuendet, M. (2013). HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol. Neurodegener. 8, 7. DOI |
21 | Holloway, M.P., DeNardo, B.D., Phornphutkul, C., Nguyen, K., Davis, C., Jackson, C., Richendrfer, H., Creton, R., and Altura, R.A. (2016). An asymptomatic mutation complicating severe chemotherapy-induced peripheral neuropathy (CIPN): a case for personalised medicine and a zebrafish model of CIPN. NPJ Genom. Med. 1, 16016. DOI |
22 | Seburn, K.L., Nangle, L.A., Cox, G.A., Schimmel, P., and Burgess, R.W. (2006). An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model. Neuron 51, 715-726. DOI |
23 | Osseni, A., Ravel-Chapuis, A., Thomas, J.L., Gache, V., Schaeffer, L., and Jasmin, B.J. (2020). HDAC6 regulates microtubule stability and clustering of AChRs at neuromuscular junctions. J. Cell Biol. 219, e201901099. DOI |
24 | Ennerfelt, H., Voithofer, G., Tibbo, M., Miller, D., Warfield, R., Allen, S., and Kennett Clark, J. (2019). Disruption of peripheral nerve development in a zebrafish model of hyperglycemia. J. Neurophysiol. 122, 862-871. DOI |
25 | Howard, J.F., Jr. (2018). Myasthenia gravis: the role of complement at the neuromuscular junction. Ann. N. Y. Acad. Sci. 1412, 113-128. DOI |
26 | Jung, J., Choi, I., Ro, H., Huh, T.L., Choe, J., and Rhee, M. (2020). march5 governs the convergence and extension movement for organization of the telencephalon and diencephalon in zebrafish embryos. Mol. Cells 43, 76-85. DOI |
27 | Chapela, D., Sousa, S., Martins, I., Cristovao, A.M., Pinto, P., Corte-Real, S., and Saude, L. (2019). A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammals. Sci. Rep. 9, 10475. DOI |
28 | Banerjee, S. and Riordan, M. (2018). Coordinated regulation of axonal microtubule organization and transport by Drosophila neurexin and BMP pathway. Sci. Rep. 8, 17337. DOI |
29 | Benoy, V., Van Helleputte, L., Prior, R., d'Ydewalle, C., Haeck, W., Geens, N., Scheveneels, W., Schevenels, B., Cader, M.Z., Talbot, K., et al. (2018). HDAC6 is a therapeutic target in mutant GARS-induced Charcot-MarieTooth disease. Brain 141, 673-687. DOI |
30 | Borg, K. and Ericson-Gripenstedt, U. (2002). Muscle biopsy abnormalities differ between Charcot-Marie-Tooth type 1 and 2: reflect different pathophysiology? Exerc. Sport Sci. Rev. 30, 4-7. DOI |
31 | Chen, S., Owens, G.C., Makarenkova, H., and Edelman, D.B. (2010). HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 5, e10848. DOI |
32 | d'Ydewalle, C., Krishnan, J., Chiheb, D.M., Van Damme, P., Irobi, J., Kozikowski, A.P., Vanden Berghe, P., Timmerman, V., Robberecht, W., and Van Den Bosch, L. (2011). HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat. Med. 17, 968-974. DOI |
33 | Butler, K.V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., and Kozikowski, A.P. (2010). Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842-10846. DOI |
34 | Cirrincione, A.M. and Rieger, S. (2020). Analyzing chemotherapy-induced peripheral neuropathy in vivo using non-mammalian animal models. Exp. Neurol. 323, 113090. DOI |
35 | Kalebic, N., Martinez, C., Perlas, E., Hublitz, P., Bilbao-Cortes, D., Fiedorczuk, K., Andolfo, A., and Heppenstall, P.A. (2013). Tubulin acetyltransferase alphaTAT1 destabilizes microtubules independently of its acetylation activity. Mol. Cell. Biol. 33, 1114-1123. DOI |
36 | Choi, H., Kim, H.J., Yang, J., Chae, S., Lee, W., Chung, S., Kim, J., Choi, H., Song, H., Lee, C.K., et al. (2020). Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models. Aging Cell 19, e13081. DOI |
37 | Dompierre, J.P., Godin, J.D., Charrin, B.C., Cordelieres, F.P., King, S.J., Humbert, S., and Saudou, F. (2007). Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571-3583. DOI |
38 | Loprest, L.J., Pericak-Vance, M.A., Stajich, J., Gaskell, P.C., Lucas, A.M., Lennon, F., Yamaoka, L.H., Roses, A.D., and Vance, J.M. (1992). Linkage studies in Charcot-Marie-Tooth disease type 2: evidence that CMT types 1 and 2 are distinct genetic entities. Neurology 42(3 Pt 1), 597-601. DOI |
39 | Antonellis, A., Ellsworth, R.E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S.Q., Jordanova, A., Kremensky, I., Christodoulou, K., Middleton, L.T., et al. (2003). Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am. J. Hum. Genet. 72, 1293-1299. DOI |
40 | Asthana, J., Kapoor, S., Mohan, R., and Panda, D. (2013). Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J. Biol. Chem. 288, 22516-22526. DOI |
41 | Wong, V.S.C., Picci, C., Swift, M., Levinson, M., Willis, D., and Langley, B. (2018). alpha-tubulin acetyltransferase is a novel target mediating neurite growth inhibitory effects of chondroitin sulfate proteoglycans and myelin-associated glycoprotein. eNeuro 5, ENEURO.0240-17.2018. |
42 | Kesner, V.G., Oh, S.J., Dimachkie, M.M., and Barohn, R.J. (2018). Lambert-Eaton myasthenic syndrome. Neurol. Clin. 36, 379-394. DOI |
43 | Sleigh, J.N., Dawes, J.M., West, S.J., Wei, N., Spaulding, E.L., Gomez-Martin, A., Zhang, Q., Burgess, R.W., Cader, M.Z., Talbot, K., et al. (2017). Trk receptor signaling and sensory neuron fate are perturbed in human neuropathy caused by Gars mutations. Proc. Natl. Acad. Sci. U. S. A. 114, E3324-E3333. |
44 | Smith, A., Kim, J.H., Chun, C., Gharai, A., Moon, H.W., Kim, E.Y., Nam, S.H., Ha, N., Song, J.Y., Chung, K.W., et al. (2022). HDAC6 inhibition corrects electrophysiological and axonal transport deficits in a human stem cell-based model of Charcot-Marie-Tooth disease (type 2D). Adv. Biol. (Weinh.) 6, e2101308. |
45 | Sleigh, J.N., Grice, S.J., Burgess, R.W., Talbot, K., and Cader, M.Z. (2014). Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice. Hum. Mol. Genet. 23, 2639-2650. DOI |
46 | Sivakumar, K., Kyriakides, T., Puls, I., Nicholson, G.A., Funalot, B., Antonellis, A., Sambuughin, N., Christodoulou, K., Beggs, J.L., Zamba-Papanicolaou, E., et al. (2005). Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain 128, 2304-2314. DOI |
47 | Sleigh, J.N., Mech, A.M., and Schiavo, G. (2020). Developmental demands contribute to early neuromuscular degeneration in CMT2D mice. Cell Death Dis. 11, 564. DOI |
48 | Son, I.H., Chung, I.M., Lee, S.I., Yang, H.D., and Moon, H.I. (2007). Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg. Med. Chem. Lett. 17, 4753-4755. DOI |
49 | Valenzuela-Fernandez, A., Cabrero, J.R., Serrador, J.M., and Sanchez-Madrid, F. (2008). HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18, 291-297. DOI |
50 | Wenzel, E.D., Speidell, A., Flowers, S.A., Wu, C., Avdoshina, V., and Mocchetti, I. (2019). Histone deacetylase 6 inhibition rescues axonal transport impairments and prevents the neurotoxicity of HIV-1 envelope protein gp120. Cell Death Dis. 10, 674. DOI |
51 | Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., and Matthias, P. (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22, 1168-1179. DOI |
![]() |